Board of Directors

Curative Biotechnology, Inc.

Paul Michaels

Chairman of the Board of Directors and President

For the past two decades, Paul has established lasting relationships with key business leaders and stakeholders in Japan and the U.S., particularly in the Life Sciences field. He has completed transactions that influenced companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals and Gilead.

He has also provided financial leadership and business development for almost 18 years to Inabata & Co. Ltd., one of Japan’s largest trading companies with $4.5 billion in annual sales. Throughout his tenure, he structured and closed major transactions that brought high-value products to the Japanese pharmaceutical market. Additionally, his other corporate responsibilities included overall evaluation of corporate asset values for purposes of divestiture or acquisition. Paul subsequently cofounded Nobelpharma, Ltd. Japan, an affiliate of Inabata & Co. Ltd., that is now one of Japan’s most successful orphan drug companies. As President of the U.S. division and a cofounder, he secured $35 million in initial capital and negotiated the license for the first designated orphan drug product in the company’s pipeline from Teva Pharmaceuticals.

As an adult-onset Type 1 diabetic, he knows firsthand how a patient can struggle to get the right diagnosis and treatment. Only 40,000 adults a year are diagnosed with Type 1 diabetes. Paul is actively involved in the Juvenile Diabetes Research Foundation (JDRF), an organization funding research for Type 1 diabetes.

Cary Sucoff

Independent Director Chairman of the Audit Committee

Cary Sucoff is an accomplished executive with over 35 years of legal and securities industry experience, having participated in the financing of over one hundred public and private companies. His expertise in legal, compliance, corporate strategy, and capital markets benefits numerous healthcare and biotechnology companies where he serves as a director or advisor. Mr. Sucoff, a former New York City prosecutor, received a B.A. from SUNY Binghamton and a J.D. from New England School of Law where he was the Managing Editor of the Law Review and graduated Magna Cum Laude. Mr. Sucoff has been a member of the Bar of the State of New York (now retired) since 1978.

Lawrence S. Zaslow

Independent Director and Chairman of the Compensation Committee

Larry Zaslow co-founded BioTheryX, Inc along with three Celgene scientists, including David Stirling, co-founder of Celgene. BioTheryX is a leader in protein degradation technology. In addition to being a founder, Mr. Zaslow also served as a director, president, and key executive over a period of fifteen years. During his tenure at BioTheryX Mr. Zaslow had primary responsibility for critical areas including strategic and operational planning, capital raising, financial planning/budget, corporate and business development, negotiation of licensing deals, investor and public relations. He helped position BioTheryX for its recent $100 million crossover round of financing and assembled a world class Scientific Advisory Board, including a Nobel Laureate. Mr. Zaslow was a founding managing director of Amphion PLC, engaged in the formation, financing, management and development of life science and technology companies seeking to commercialize their intellectual property. He earned his BA in Economics from Brandeis University, and his MBA in Finance from the Columbia Business School.

Thomas Poss

Board Member

Board member Tom Poss is a 30-year veteran of the securities industry, starting in high school in a local brokerage office and eventually getting licensed in the 1990s and working on the NYSE floor first as a clerk rising later to CCO and CFO roles. Currently he serves as the CFO for a 300+ person regional Broker/Dealer with 4.5 billion under management. He is SEC/FINRA licensed series 3, 4, 7, 14, 14a, 24, 28, 55, 63, 79 and 99.

Active in local politics and public health charitable giving, his lifelong interest in science and medicine presaged his association with Curative Biotechnology.